Should I buy or sell Scholar Rock stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRRK shares. View SRRK analyst ratings or view top-rated stocks .

What is Scholar Rock's stock price target for 2024?

6 equities research analysts have issued 1 year price objectives for Scholar Rock's stock. Their SRRK share price targets range from $20.00 to $30.00. On average, they predict the company's share price to reach $25.17 in the next twelve months. This suggests a possible upside of 88.8% from the stock's current price. View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts .

How have SRRK shares performed in 2024?

Scholar Rock's stock was trading at $18.80 on January 1st, 2024. Since then, SRRK shares have decreased by 29.1% and is now trading at $13.33. View the best growth stocks for 2024 here .

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SRRK earnings forecast .

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC) , Coherus BioSciences (CHRS) , CTI BioPharma (CTIC) , Exelixis (EXEL) , GlycoMimetics (GLYC) , Nektar Therapeutics (NKTR) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA) .

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SRRK

Scholar Rock (SRRK) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free SRRK Stock Alerts

$13.54

+0.21 (+1.58%)

(As of 10:09 AM ET)

Compare

Today's Range: $13.15
▼
$13.56
50-Day Range: $13.20
▼
$17.76
52-Week Range: $5.56
▼
$21.17

Volume: 29,479 shs
Average Volume: 776,399 shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.17

Get Scholar Rock alerts:

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating: Buy
3.17 Rating Score
Upside/Downside: 88.8% Upside
$25.17 Price Target
Short Interest: Bearish
16.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 0.83
Based on 3 Articles This Week
Insider Trading: Selling Shares
$534,887 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.01) to ($1.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

71st out of 928 stocks

Biological Products, Except Diagnostic Industry

9th out of 156 stocks

4.6

Analyst's Opinion

Consensus Rating
Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Scholar Rock has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
16.08% of the outstanding shares of Scholar Rock have been sold short.
Short Interest Ratio / Days to Cover
Scholar Rock has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Scholar Rock has recently increased by 18.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Scholar Rock does not currently pay a dividend.
Dividend Growth
Scholar Rock does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Scholar Rock has received a 71.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Scholar Rock is -0.82.

3.2

News and Social Media Coverage

News Sentiment
Scholar Rock has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Scholar Rock this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for SRRK on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
7 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $534,887.00 in company stock.
Percentage Held by Insiders
26.20% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Scholar Rock are expected to grow in the coming year, from ($2.01) to ($1.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Scholar Rock is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Scholar Rock is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Scholar Rock has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SRRK Stock News Headlines

April 12, 2024 | businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2024 | finance.yahoo.com

SRRK Oct 2024 15.000 put

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

April 2, 2024 | finance.yahoo.com

SRRK Oct 2024 20.000 call

March 28, 2024 | msn.com

Stocks See Support from Improved Soft-Landing Prospects

March 23, 2024 | seekingalpha.com

SRRK Scholar Rock Holding Corporation

March 20, 2024 | finance.yahoo.com

Scholar Rock Holding Corp Reports Full Year 2023 Financial Results

March 20, 2024 | finance.yahoo.com

Scholar Rock Holding Corp (2QK.BE)

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Scholar Rock on Strong SMA Pipeline and Strategic Developments

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Scholar Rock Holding on Strong Drug Pipeline Potential and Expansion into Obesity Market

March 19, 2024 | investorplace.com

SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023

March 19, 2024 | markets.businessinsider.com

Scholar Rock Reports Wider Loss For Full Year

March 19, 2024 | businesswire.com

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

March 17, 2024 | finance.yahoo.com

SRRK Apr 2024 10.000 put

March 17, 2024 | finance.yahoo.com

SRRK Apr 2024 22.500 call

March 16, 2024 | ca.finance.yahoo.com

SRRK Oct 2024 5.000 call

March 16, 2024 | ca.finance.yahoo.com

SRRK Jul 2024 10.000 call

March 16, 2024 | ca.finance.yahoo.com

SRRK Oct 2024 25.000 call

March 15, 2024 | businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2024 | finance.yahoo.com

SRRK Mar 2024 7.500 put

February 28, 2024 | finance.yahoo.com

Scholar Rock to Participate in Upcoming Investor Conferences

February 28, 2024 | businesswire.com

Scholar Rock to Participate in Upcoming Investor Conferences

February 21, 2024 | wsj.com

Scholar Rock Holding Corp.

February 17, 2024 | ca.finance.yahoo.com

SRRK Mar 2024 15.000 call

February 16, 2024 | finance.yahoo.com

SRRK Mar 2024 15.000 put

February 16, 2024 | businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SRRK
CUSIP: N/A
CIK: 1727196
Web: www.scholarrock.com
Phone: (857) 259-3860
Fax: 866-493-4935
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.17
High Stock Price Target: $30.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +88.8%
Consensus Rating: Buy
Rating Score (0-4): 3.17
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-165,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.48%
Return on Assets: -57.10%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 8.80
Quick Ratio: 8.80

Sales & Book Value

Annual Sales: $33.19 million
Price / Sales: 31.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.12 per share
Price / Book: 4.27

Miscellaneous

Outstanding Shares: 77,866,000
Free Float: 57,465,000
Market Cap: $1.04 billion
Optionable: Optionable
Beta: 0.90

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Jay Thomas Backstrom M.D. (Age 69)
M.P.H., President, CEO & Director
Comp: $686.49k
Mr. Edward H. Myles MBA (Age 52)
CFO, COO & Treasurer
Comp: $668.49k
Ms. Junlin Ho J.D. (Age 45)
General Counsel & Corporate Secretary
Comp: $563.73k
Mr. Mo Qatanani Ph.D. (Age 50)
Chief Scientific Officer
Rushmie Nofsinger
Vice President of Corporate Affairs & Investor Relations
Ms. Caryn Parlavecchio (Age 52)
Chief Human Resources Officer
Ms. Lisa Amaya Price
Senior Vice President of Human Resources
Ms. Erin Moore (Age 49)
Senior Vice President of Finance
Mr. Ryan Iarrobino
Senior Vice President of Clinical Development & Operations
Dr. Jing L. Marantz M.B.A. (Age 59)
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.
What is Scholar Rock's stock price target for 2024?: 6 equities research analysts have issued 1 year price objectives for Scholar Rock's stock. Their SRRK share price targets range from $20.00 to $30.00. On average, they predict the company's share price to reach $25.17 in the next twelve months. This suggests a possible upside of 88.8% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.
How have SRRK shares performed in 2024?: Scholar Rock's stock was trading at $18.80 on January 1st, 2024. Since then, SRRK shares have decreased by 29.1% and is now trading at $13.33.
View the best growth stocks for 2024 here.
When is Scholar Rock's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SRRK earnings forecast.

How were Scholar Rock's earnings last quarter?: Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01.
What other stocks do shareholders of Scholar Rock own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).
When did Scholar Rock IPO?: Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Scholar Rock?: Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Scholar Rock (SRRK) Stock Price, News & Analysis

Scholar Rock MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Scholar Rock Stock (NASDAQ:SRRK)

SRRK Stock Price History

SRRK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SRRK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™